The Prognosis And Influencing Factors Of Endocrine Therapy For Prostate Cancer In Different Ethnic Groups Of Xinjiang

Objective: Ethnic disparities exist in prostate cancer (PCa); the study was aimed tounderstand the associations between the disparities as well as other factors and PCapatients’ prognosis, by analyzing the factors that may influence the prognosis of PCapatients, from different ethnic groups in Xinjiang, treated with endocrine therapy.Methods: We retrospectively analyzed the clinicopathological data of228cases of PCareceived endocrine therapy in our hospital from January2002to October2010, Overallsurvival and disease specific survival rates for patients were analyzed by Kaplan-Meiermethod, the factors that may influence the prognosis and survival of PCa patients wereusing univariate (log-rank test) and multivariate Cox proportional hazard models. Results:1-,3-and5-year Overall survival rates were92.7%、66.8%and37.2%,disease specificsurvival rates were93.2%,68.3%and40.1%for all228patients, respectively.3-yeardisease specific survival rates were73.6%and54.2%(P=0.025) for Han patients andother minorities (Uighur+Kazakh) respectively.3-year disease specific survival was72.2%for maximal androgen blockade (MAB), and56.3%for castration or antiandrogenmonotherapy (P=0.004). Univariate analysis by log-rank test showed that, nationality,pretreatment ECOG performance state score (EPS score), stage, Gleason score (GS),pretreatment total prostate specific antigen (tPSA), serum alkaline phosphatase (ALP),hemoglobin (HGB)level and MAB therapy were the important factors that impacted onthe survival of PCa patients treated with endocrine therapy. Multivariate analysis by Coxmodel showed that nationality, pretreatment EPS score, stage, Gleason score,pretreatment HGB level and MAB therapy were the significant independent prognosticfactors in PCa patients treated with endocrine therapy. Conclusion: MAB therapy provides longer survival time than castration or antiandrogen monotherapy for PCapatients treated with endocrine therapy. Nationality, stage, Gleason score, pretreatmentHGB level, pretreatment EPS score and MAB therapy are significant independent factorsinfluencing survival.